Introduction
This document presents guidance regarding the characterization of the expression construct for the production of recombinant DNA protein products in eukaryotic and prokaryotic cells. The expression construct is defined as the expmsion vector containing the coding sequence of the recombinant protein.
Characterization Of the expression construct was one of the issues addressed in the "Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology", 199% Since that time there have been advances in analytical technologies for protein and nucleic acid characterization, which have occurred in parallel with advances in fermentation and cell culture technologies. This document is intended to extend and clarify the types of information that are considered valuable in assessing the structure of the expression construct used to produce recombinant DNA proteins. In developing this document, we have attempted to take into consideration recent advances in biochemical technology, past history with different production systems, information derived from international meetings, and comments submitted to the FDA. In particular, these issues were discussed in detail at the "1991 International Workshop on Continuous Cell Lines: Current Issues'. Scientists at the Center for Biologics Evaluation and Research (CBER) believe that the supplemental guidance in this document reflects commonly held positions within the scientific community and that this document clarifies the testing to be performed to characterize nucleic acids andã ssess genetic stability. CBER also recognizes that this area has been one of special concern to the industry and invites comments on this document that can be considered in subsequent revisions to the Points to Consider in the page -l- is not intended to detect few levels of variant sequences, but rather to validate that the predominant protein species prior to purification will have the correct amino acid sequence following the manipulations of cells during full scale production. Where th8 production cells have multiple integrated copies Of the expression construct, not all of which may be transcriptionally active, examination of the transcription product itself by mRNA or CDNA analysis may be more appropriate than genomic DNA analysis. Analytical approaches that examine a bulk population of nucleic acid, such as those performed on material amplified by the polymeraS chain reaction, may be preferable to approaches depending on selection of individual DNA don8S.
The following sections describe information that should be supplied regarding the charaCt8rizatiOn of the expression construct during the page -3-development and validation of the cell expression clone for production. These recommendations are based On current technology, and it is anticipated that they will be modified aS newer techniques are developed and as our knowledge grows in this area.
Ill. Characterization of Expression Constructs
A. w Df!&&IB -The manufacturer should describe the method used to prepare the DNA coding for the protein, including the cell and origin of the source nucleic acid.
The steps in the assembly of the expression construct should be and methodology, should be described. If a new MCB is to be generated by expression construct transfer into host cells, followed by clonal selection, then acceptance criteria for both the new clone and the protein produced by the clone should be described. The identity and purity of the cells in each MCB should be assured by testing appropriate phenotypic markers, e.g., auxotroPhY
and antibiotic resistance. Each MCB should be characterized for adventitious agents, if appropriate, as described in the "Points to Consider in the page -5
Characterization of Cell Lines to Produce Biological Products ', 1987 . The MCB should be tested periodically to ensure the viability of the cells. It is important to note that tests on End of Production cells described above are m intended to be carried out at the end of &&h production run. At the end of sach production cycle, cells should be analyzed for relevant phenotypic or genotypic markers, and for contamination by adventitious agen?s as described in the "Points to Consider in the Characterization of Cell Lines to Produce Biological Products", 1987. Data on the consistency of yield from fullscale culture should be maintained, and criteria for the rejection of culture lots should be established.
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IV. Conclusion
The characterization of the expression construct and the purified protein is important to ensure the consistent production of a recombinant ONA derived product. At present, it is believed that analytical data derived from either nucleic acid testing or protein structural testing alane do not allow for a complete evaluation of the identity and purity of a recombinant protein product.
As technology advances, CBER will reassess this position and revise this document.
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